Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
Wissenschaftlicher Artikel
Autoren
Kampa-Schittenhelm, Kerstin Maria
Heinrich, Michael Charles
Akmut, Figen
Döhner, Hartmut
Doehner, Konstanze
Institutionen
UKU. Klinik für Innere Medizin IIIErschienen in
Molecular cancer ; 12 (2013). - Art.-Nr. 19. - ISSN 1476-4598
Link zur Veröffentlichung
https://dx.doi.org/10.1186/1476-4598-12-19Förderinformationen
Deutsche Krebshilfe Foundation
IZKF Program of the Medical Faculty Tubingen
Carreras Scholarship Program
Leukemia and Lymphoma Society
Department of Veterans Affairs
etc.
IZKF Program of the Medical Faculty Tubingen
Carreras Scholarship Program
Leukemia and Lymphoma Society
Department of Veterans Affairs
etc.